*Applications will be reviewed on a rolling-basis.
A postdoctoral research opportunity is currently available in the Division of Plasma Protein Therapeutics (DPPT), within the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
For this research project, the participant will join a research program that broadly studies the immune responses to therapeutic proteins (immunogenicity). They will collaborate with experimental biologists and immunologists as well as clinicians to identify genetic risk factors for immunogenicity. The following articles in the literature provide examples of the range of work performed in our group:
- Front. Immunol. 10: 2894, 2019
- Blood Adv. 3: 2668-2678, 2019
- AAPS J. 21: 96, 2019
- Blood Adv. 3: 1429-1440, 2019
- Mol Ther Methods Clin Dev. 10: 105-112, 2018
- Sci. Transl. Med. 9: eaag1286, 2017
- Blood 125: 223-228, 2015
- Nature Med. 19: 1318-1324, 2013
- PLoS Comput. Biol., 9, e1003066, 2013
- Nature Biotechnol. 29: 870-873, 2011
Anticipated Appointment Start Date: January 1, 2021
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for four months, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2021-0002) in your email.